At a glance: Departmental Evaluation Plan for the Public Health Agency of Canada, 2023-24 to 2027-28
The OAE Departmental Evaluation Plan for Public Health Agency of Canada (PHAC) describes the Program Evaluation Division's scheduled work for the five-year period from 2023-24 to 2027-28. The Plan was developed to meet PHAC's commitments under the Policy on Results (2016), which requires that each department prepare a five-year plan, updated annually.
The projects included in this Evaluation Plan were selected to ensure full coverage of all Grants and Contributions spending over $5 million annually over a five-year period, and that prior commitments in Treasury Board (TB) submissions were met, as well as addressing the information needs of program management, coverage of program risks, and optimal use of resources. The Departmental Results Framework (DRF), program inventory, and performance information profiles developed by PHAC have formed the basis for this plan.
With COVID-19 no longer considered a global health emergency, PHAC's work has shifted focus to its ongoing program activities. As such, the present Departmental Evaluation Plan (DEP) ensures that the Office of Audit and Evaluation (OAE) continues to meet its reporting commitments under the Financial Administration Act (FAA) and any Treasury Board (TB) submission commitments, while also addressing key risks and senior management and program management information needs. Given the importance of the COVID-19 response, the impact of the pandemic on PHAC activities will continue to be assessed in most evaluations in the DEP, notably in the area of data modernization, border and travel health, and emergency preparedness and response.
Planning for evaluation
Over the next five years, OAE plans to conduct 35 evaluations that involve PHAC: 25 will focus exclusively on PHAC activities, and one evaluation will examine the activities of both PHAC and Health Canada. The remaining nine projects are horizontal evaluations led by other government departments or agencies. A yearly breakdown is provided in Table 1. Table 2 outlines the direct program spending (DPS) by core responsibility for all scheduled evaluations for the next five years.
Lead | 2023-24 | 2024-25 | 2025-26 | 2026-27 | 2027-28 | Total |
---|---|---|---|---|---|---|
PHAC | 4 | 5 | 6 | 6 | 4 | 25 |
PHAC and HC | 0 | 0 | 1 | 0 | 0 | 1 |
Horizontal (OGD-led) | 1 | 1 | 1 | 1 | 5 | 9 |
Total | 5 | 6 | 8 | 7 | 9 | 35 |
Table 2 – Coverage of direct program spending (DPS)
Program | Evaluations planned in the next five years | Fiscal year of approval | 2023-24 spending covered by evaluation ($)Footnote 1 | Rationale for not evaluating program or spending |
---|---|---|---|---|
Core Responsibility | Health Promotion and Chronic Disease Prevention ($406,889,035) | |||
Health Promotion ($301,225,679) | Indigenous Early Learning and Child Care Initiative | 2023-24 | $29,511,259 | N/A |
Aging, Seniors and Dementia | 2023-24 | $16,247,549 | N/A | |
Nutrition North Canada | 2024-25 | $335,000 | N/A | |
Preventing Gender-Based Violence: the Health Perspective (formerly Supporting the Health of Survivors of Family Violence) | 2024-25 | $6,250,000 | N/A | |
PHAC's Mental Health Activities | 2025-26 | $89,567,043 | N/A | |
Maternal and Child Health Programs | 2025-26 | $98,811,943 | N/A | |
Aboriginal Head Start in Urban and Northern Communities | 2027-28 | $33,347,831 |
N/A | |
Fetal Alcohol Spectrum Disorder (FASD) and Autism Spectrum Disorder (ASD) Initiatives | 2027-28 | $776,780 | N/A | |
Action Plan for Official Languages | 2027-28 | $2,088,475 | N/A | |
Horizontal Evaluation of the Legalization and Regulation of Cannabis | 2027-28 | $651,337 | N/A | |
Impact Assessment and Regulatory Processes (IARP) Horizontal Initiative | 2027-28 | $400,000 | N/A | |
National Action Plan on Violence Against Women and Gender-Based Violence | 2027-28 | $12,238,462 | N/A | |
Contribution Funding for the Centre for Aging and Brain Health Innovation (CABHI) | N/A | $11,000,000 | The timing for the evaluation will be determined during the development of a future Departmental Evaluation Plan. It was recently evaluated in 2019-20. | |
Chronic Disease Prevention ($34,693,013) | Public Health Agency of Canada's (PHAC) Funding of ParticipACTION's Let's Get Moving Initiative | 2023-24 | $0 | N/A |
Healthy Canadians and Communities Fund | 2025-26 | $27,784,076 | N/A | |
Health Portfolio's Tobacco and Vaping Activities | 2025-26 | $205,000 | N/A | |
Office of International Affairs | 2025-26 | $0 | N/A | |
Type 2 Diabetes Prevention Challenge | N/A | $4,935,000 | This is a time limited contribution (Start Date: 2021-22 – End Date: 2023-24) with low materiality | |
Development of a National Diabetes Framework | N/A | $1,768,937 | This is a time limited contribution (Start Date: 2021-22 - End Date: 2025-26) with low materiality. | |
Evidence for Health Promotion, and Chronic Disease and Injury Prevention ($70,970,343) | Aging, Seniors and Dementia | 2023-24 | $1,986,564 | N/A |
National Collaborating Centres | 2023-24 | $2,921,002 | N/A | |
Nutrition North Canada | 2024-25 | $50,000 | N/A | |
PHAC's Mental Health Activities | 2025-26 | $1,734,219 | N/A | |
Healthy Canadians and Communities Fund | 2025-26 | $1,333,000 | N/A | |
Evidence for Health Promotion Chronic Disease and Injury Prevention | 2026-27 | $38,291,072 | N/A | |
Office of the Chief Dental Officer | 2026-27 | $567,827 | N/A | |
Horizontal Evaluation of the Canadian Drug and Substance Strategy (Including the overdose crisis in Canada) | 2027-28 | $1,545,658 | N/A | |
Fetal Alcohol Spectrum Disorder (FASD) and Autism Spectrum Disorder (ASD) Initiatives | 2027-28 | $1,499,000 | N/A | |
National Action Plan on Violence Against Women and Gender-Based Violence | 2027-28 | $241,543 | N/A | |
Pan-Canadian Joint Consortium for School Health | N/A | $250,000 | This funding doesn't fit with other children's programs and has very low materiality. | |
Post COVID-19 Condition | N/A | $20,550,458 | The timing for the evaluation will be determined during the development of a future Departmental Evaluation Plan. | |
Core Responsibility | Infectious Diseases Prevention and Control ($3,356,032,806) | |||
Laboratory Science Leadership and Services ($175,242,596) | Sexually Transmitted and Blood-Borne Infections | 2023-24 | $6,225,772 | N/A |
Emergency Preparedness and Response | 2024-25 | $74,016,531 | N/A | |
Data Modernization | 2024-25 | $44,110,560 | N/A | |
Genomics Research and Development Initiative (GRDI) | 2025-26 | $2,304,596 | N/A | |
Infectious Disease and Climate Change | 2025-26 | $1,116,689 | N/A | |
Adapting to Impacts of Climate Change (Roll-up of Departmental Evaluation) | 2026-27 | $0 | N/A | |
Medical Countermeasures Capacity | 2026-27 | $45,086,880 | N/A | |
Food-borne and Water-borne Enteric Diseases | 2027-28 | $1,921,568 | N/A | |
Public Health Scholarship and Capacity Building Initiative (PHSCBI) | N/A | $460,000 | The timing for the evaluation will be determined during the development of a future Departmental Evaluation Plan. | |
Communicable Diseases and Infection Control ($90,243,807) | Sexually Transmitted and Blood-Borne Infections | 2023-24 | $34,244,000 | N/A |
National Collaborating Centres | 2023-24 | $973,666 | N/A | |
Emergency Preparedness and Response | 2024-25 | $43,157,944 | N/A | |
Health Care-Associated Infections | 2026-27 | $2,678,197 | N/A | |
Tuberculosis | 2026-27 | $0 | N/A | |
Horizontal Evaluation of the Canadian Drug and Substance Strategy (Including the overdose crisis in Canada) | 2027-28 | $7,000,000 | N/A | |
PHAC Blood Safety Program | 2027-28 | $2,190,000 | N/A | |
Immunization and Vaccine Preventable Disease ($3,071,452,799) |
Immunization and Respiratory Infectious Diseases | 2024-25 | $3,005,702,799 | N/A |
Sero-Surveillance Consortium | 2024-25 | $65,500,000 | N/A | |
COVID-19 Individual Risk Assessment Tool | N/A | $250,000 | This is a time limited contribution (Start Date: June 25, 2021- End Date: March 31, 2023) with low materiality. | |
Foodborne and Zoonotic Disease ($19,093,604) |
National Collaborating Centres | 2023-24 | $973,666 | N/A |
Emergency Preparedness and Response | 2024-25 | $7,637,668 | N/A | |
Office of International Affairs | 2025-26 | $0 | N/A | |
Infectious Disease and Climate Change | 2025-26 | $5,385,652 | N/A | |
Genomics Research and Development Initiative (GRDI) | 2025-26 | $1,470,317 | N/A | |
Adapting to Impacts of Climate Change (Roll-up of Departmental Evaluation) | 2026-27 | $0 | N/A | |
Food-borne and Water-borne Enteric Diseases | 2027-28 | $3,626,301 | N/A | |
Core Responsibility | Health Security ($299,710,417) | |||
Emergency Preparedness and Response ($284,127,084) | National Collaborating Centres | 2023-24 | $973,666 | N/A |
Emergency Preparedness and Response | 2024-25 | $282,746,624 | N/A | |
Biosecurity Program | 2025-26 | $319,623 | N/A | |
Food-borne and Water-borne Enteric Diseases | 2027-28 | $87,171 | N/A | |
Biosecurity ($8,723,072) |
Biosecurity Program | 2025-26 | $8,723,072 | N/A |
Border Health Security ($6,860,261) |
Biosecurity Program | 2025-26 | $90,539 | N/A |
Border and Travel Health Program | 2026-27 | $6,769,722 | N/A |
Footnotes
- Footnote 1
-
To obtain detailed estimates on program budgets, annual data for 2023-24 is presented. This financial data was extracted by the Office of the Chief Financial Officer on March 21, 2023. As a result, these budget figures may not fully align with those contained in other corporate reporting documents such as the Departmental Plan, the Departmental Results Report, or the Three-Year Transfer Payment Program Plan.
Page details
- Date modified: